SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
54.60    -1.40 (-2.50%)
Bid:
52.60
Ask:
56.60
Spread: 4.00 (7.605%)
Market Cap: £45.60m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Offer Update

12 Jun 2008 12:01

RNS Number : 5700W
Flomerics Group PLC
12 June 2008
 



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

12 June 2008

Flomerics Group plc  (the "Company")

Continued Discussions

Further to the previously announced ongoing discussions with Autodesk, Inc. ("Autodesk") and pursuant to the requirements of the City Code on Takeovers and Mergers, the Company has been informed that should any offer be forthcoming from Autodesk, the consideration for such would be satisfied solely in cash.

As has been previously announced, at this stage there can be no certainty that an offer from Autodesk will be forthcoming, nor in the event of such, as to the terms on which any such offer might be made. 

This announcement has been made with the consent of Autodesk.

 

Enquiries:

Flomerics Group PLC

Gary Carter

Keith Butcher

Tel: 020 8487 3000

Jefferies International Ltd

Andres Pieczanski

Sarah McNicholas

Tel: 020 7029 8000

Oriel Securities Ltd

Andrew Edwards

Michael Shaw

Tel: 020 7710 7600

Citigate Dewe Rogerson

Ginny Pulbrook

Seb Hoyle

Tel: 020 7638 9571

  Flomerics Shares in Issue

Pursuant to Rule 2.10 of the City Code, Flomerics confirms that it has 22,935,250 ordinary shares of one penny each in issue and admitted to trading on the Alternative Investment Market of the London Stock Exchange (ISIN GB0003436192).

Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Takeover Code (the 'Code'), if any person is, or becomes, 'interested' (directly or indirectly) in 1% or more of any class of 'relevant securities' of Flomerics, all 'dealings' in any 'relevant securities' of that company (including by means of an option in respect of, or a derivative referenced to, any such 'relevant securities') must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the 'offer period' otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an 'interest' in 'relevant securities' of Flomerics, they will be deemed to be a single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the Code, all 'dealings' in 'relevant securities' of Flomerics by a potential offeror or by Flomerics, or by any of their respective 'associates', must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

'Interests in securities' arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a 'dealing' under Rule 8, you should consult the Panel.

Other

Jefferies International Limited, which is authorised and regulated in the UK by The Financial Services Authority, is acting exclusively for Flomerics and no one else in connection with the Mentor Offer and, accordingly, will not be responsible to anyone other than Flomerics for providing the protections afforded to customers of Jefferies International Limited or for providing advice in relation to the Mentor Offer or in relation to the contents of this document or any transaction or arrangement or other matter referred to herein.

Oriel Securities Limited ('Oriel Securities'), which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting for Flomerics and no-one else in connection with the matters referred to herein and will not be responsible to anyone other than Flomerics for providing the protections afforded to clients of Oriel Securities or for giving advice in relation to such matters.

Note to Editors

Flomerics (www.flomerics.com) is a world-leading developer of engineering simulation software and services for analysis of fluid flow, heat transfer. Flomerics' business model is drastically different from traditional analysis because its software is designed to be embedded deeply into the design process and used by mainstream design engineers, not just by analysis specialists.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPUURARWRRNAAR
Date   Source Headline
10th Jul 20177:00 amRNSAcquisition of Orange County Ltd, County Durham
7th Jul 201712:26 pmRNSHolding(s) in Company
23rd Jun 20177:00 amRNSFlowtech adds technical expertise & product
26th May 20171:34 pmRNSHolding(s) in Company
25th May 201711:34 amRNSResult of AGM
25th May 20177:00 amRNSAGM Statement
22nd May 201712:45 pmRNSIssue of Equity
8th May 20175:11 pmRNSHolding(s) in Company
26th Apr 20177:00 amRNSAnnual Financial Report & AGM
4th Apr 20177:01 amRNS2017 Q1 Trading Update
4th Apr 20177:00 amRNSFinal statement of results - year ended 31.12.16
30th Mar 201711:45 amRNSHolding(s) in Company
29th Mar 201711:33 amRNSResult of General Meeting
13th Mar 20176:07 pmRNSPosting of Circular
10th Mar 201711:06 amRNSConfirmation of successful £10 million fundraise
10th Mar 20177:15 amRNSClose of accelerated bookbuild
9th Mar 20175:03 pmRNSProposed Accelerated Bookbuild
6th Feb 20174:23 pmRNSHolding(s) in Company
23rd Jan 20177:00 amRNSTrading, Acquisition, Strategy & Notice of Results
20th Jan 20177:00 amRNSAppointment of Joint Corporate Broker
8th Nov 20167:00 amRNSDirector/PDMR Shareholding
21st Sep 20167:00 amRNSHolding(s) in Company
13th Sep 20167:00 amRNS2016 HALF-YEAR REPORT - SIX MONTHS TO 30 JUNE
2nd Aug 20167:00 amRNSAcquisition, Trading Update & Notice of HY Results
30th Jun 201611:54 amRNSFlowtech-winner at 2016 Regional Business Awards
2nd Jun 20167:00 amRNSGrants under the Management Incentive Plan
1st Jun 20161:40 pmRNSResult of AGM
1st Jun 20167:00 amRNSANNUAL GENERAL MEETING - TRADING UPDATE
27th May 20167:00 amRNSHolding(s) in Company
13th May 201611:51 amRNSDirector/PDMR Shareholding
6th May 20161:59 pmRNSHolding(s) in Company
3rd May 20165:23 pmRNS2015 Annual Financial Report & Notice of AGM
12th Apr 20169:10 amRNS2015 Final results - Replacement
6th Apr 201610:31 amRNSAdoption of Financial Reporting Standard (FRS) 101
26th Feb 20161:18 pmRNSHolding(s) in Company
21st Jan 20166:04 pmRNSHolding(s) in Company
19th Jan 20164:36 pmRNSHolding(s) in Company
18th Jan 20167:00 amRNSTrading Update & Notice of Annual Results
21st Dec 20157:00 amRNSHolding(s) in Company
3rd Dec 20154:11 pmRNSHolding(s) in Company
24th Nov 20157:00 amRNSShare Purchases by Directors
5th Nov 20157:00 amRNSHolding(s) in Company
4th Nov 201510:09 amRNSHolding(s) in Company
3rd Nov 20157:00 amRNSExercise of Options and Total Voting Rights
3rd Nov 20157:00 amRNSHolding(s) in Company
29th Oct 20157:13 amRNSDirector Declaration
23rd Oct 20157:00 amRNSDirectorate Change
16th Sep 20158:05 amRNSDirector's Dealings
8th Sep 20157:01 amRNSEaton - Master Trading Agreement
8th Sep 20157:00 amRNSHalf Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.